Alergia e Imunologia

Estudo randomizado fase 2 | Uso profilático de garadacimabe em pacientes com angioedema hereditário.

21 Mar, 2022 | 16:08h

Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial – The Lancet (link para o resumo – $ para o texto completo)

Comentário: Garadacimab significantly reduces frequency of hereditary angioedema exacerbations – Physician’s Weekly

---

Seguimento de dados de 2 estudos randomizados | Eficácia e segurança do uso de upadacitinibe em pacientes com dermatite atópica moderada a grave.

21 Mar, 2022 | 15:55h

Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials – JAMA Dermatology

---

Outro estudo sugere que a 3ª dose de vacina é necessária para proteger as populações contra a variante Ômicron.

11 Mar, 2022 | 15:13h

Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study – The BMJ

Comunicado de imprensa: Third vaccine dose critical for protecting populations against omicron variant – BMJ Newsroom

 

Comentário no Twitter

mRNA vaccines are highly effective in preventing covid-19 associated hospital admissions related to the alpha, delta, and omicron variants. But three doses are needed to achieve a similar level of protection against omicron, finds a large US study: https://t.co/YMm176gmby

— The BMJ (@bmj_latest) March 10, 2022

 

---

Estudo randomizado | Glicocorticoide inalatório de demanda reduz exacerbações graves em adultos negros e latinos com asma moderada a grave.

9 Mar, 2022 | 13:56h

Reliever-Triggered Inhaled Glucocorticoid in Black and Latinx Adults with Asthma – New England Journal of Medicine (link para o resumo – $ para o texto completo)

Comentário: Patient-centered intervention improved asthma outcomes for Black and Latinx adults – Brigham and Women’s Hospital

---

Dois imunologistas explicam quanto tempo dura a imunidade protetora contra COVID-19 após infecção ou vacinação.

8 Mar, 2022 | 18:34h

How long does protective immunity against COVID-19 last after infection or vaccination? Two immunologists explain – The Conversation

---

M-A | Eficácia das vacinas contra Covid-19 em pacientes imunocomprometidos.

8 Mar, 2022 | 16:16h

Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis – The BMJ

Comunicado de imprensa: Study suggests additional covid-19 vaccine doses for immunocompromised patients – BMJ Newsroom

Conteúdos relacionados: Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review.

 

Comentário no Twitter

NEW RESEARCH: Additional doses of covid-19 vaccine are recommended for immunocompromised patients, especially for organ transplant recipients who are least able to make antibodies to fight off coronavirus, suggests new research https://t.co/l2IWfSb0zd @sundar__raghav

— The BMJ (@bmj_latest) March 3, 2022

 

---

[Preprint] Estudo mostra efetividade significativamente reduzida da vacina da Pfizer em crianças de 5 a 11 anos após o surgimento da variante Ômicron.

1 Mar, 2022 | 15:36h

Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the Emergence of the Omicron Variant – medRxiv

Comentários:

Pfizer Covid vaccine is less effective in kids 5 to 11, study finds – STAT

Pfizer Covid-19 vaccine effectiveness fell quickly for kids during Omicron surge but still offered some protection against severe disease – CNN

More mask mandates fall as poor COVID vaccine protection noted in young kids – CIDRAP

---

Diretriz | Plasmaférese e dosagem de glicocorticoides para pacientes com vasculite associada a ANCA.

28 Fev, 2022 | 13:35h

Plasma exchange and glucocorticoid dosing for patients with ANCA-associated vasculitis: a clinical practice guideline – The BMJ

Ver também: The effects of plasma exchange in patients with ANCA-associated vasculitis: an updated systematic review and meta-analysis – The BMJ

 

Comentário no Twitter

New rapid recommendation makes a weak recommendation against plasma exchange in patients with low risk of end stage kidney disease, and a weak recommendation in favour of plasma exchange in patients with moderate-high risk of ESKD https://t.co/PeEjSuRIxI #BMJInfographic pic.twitter.com/YR55t6XYhS

— The BMJ (@bmj_latest) February 25, 2022

 

---

[Preprint] Quarta dose da vacina contra COVID fornece somente um leve reforço contra a infecção pela variante Ômicron.

24 Fev, 2022 | 15:50h

Fourth dose of COVID vaccine offers only slight boost against Omicron infection – Nature

Estudo original: 4th Dose COVID mRNA Vaccines’ Immunogenicity & Efficacy Against Omicron VOC – medRxiv

---

Dois amplos estudos de base populacional mostram um risco ligeiramente aumentado de eventos trombóticos após vacinação contra COVID-19 com a vacina da AstraZeneca.

24 Fev, 2022 | 15:47h

Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: A population-based cohort study of 46 million adults in England – PLOS Medicine

Ver também: First dose ChAdOx1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis: A pooled self-controlled case series study of 11.6 million individuals in England, Scotland, and Wales – PLOS Medicine

Comentários:

Two studies find only small elevated risk of blood clots following AstraZeneca COVID-19 vaccination – PLOS

Two Large Studies Affirm Rare Thrombosis Risk With ChAdOx1 COVID-19 Vax – TCTMD

---